Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Apellis Pharmaceuticals Inc APLS

Healthcare Biotechnology
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic... see more

Current News (NDAQ:APLS)

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 5 days ago

Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 12 days ago

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

GlobeNewswire December 3, 2025

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire November 25, 2025

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

GlobeNewswire November 12, 2025

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

GlobeNewswire November 5, 2025

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

GlobeNewswire October 30, 2025

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

GlobeNewswire October 20, 2025

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

GlobeNewswire October 16, 2025
View More News ››

Opinion & Analysis (NDAQ:APLS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:APLS)

Be the first to post on this bullboard.

Oregen Energy Corp

Oregen Energy Corp

Oregen Energy Corp., an energy and resource exploration company, focuses on acquiring and advancing natural resources ...
View More »

Podcasts